Searched for
SPECIALTY PHARMACY
These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsFrom a macro perspective, it is clearly a good time to be bullish. But as valuations remain high in parts of the market despite the recent ...- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 26%On Thursday evening, US President Trump said he would “hit Iran hard tonight”. Then, as the world waited with bated breath, came the announ...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsThe latest escalation in the US-Iran war means that crude oil price is back as a risk for India. Although we are in a market already strugg...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsIf the US-Iran ceasefire holds, the markets may see some recovery. The movement of crude oil prices and its impact on the markets supports ...
- Time to take measured and logical risks? 5 small-caps from different sectors with upside potential of up to 26%Given the fluctuating situation in the Gulf region because of the US-Iran conflict, there is no guarantee that the market will not fall fur...
- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- Apollo Hospitals FY26 profit jumps 34% to Rs 1,942 crore on growth across core businessesApollo Hospitals announced robust financial results for the fourth quarter and the full fiscal year 2026. Consolidated revenue and net prof...
- Bayer bets big on 'self-care' market to deepen India playGlobal pharma major Bayer is significantly expanding its consumer healthcare presence in India, targeting the burgeoning self-care market e...
- These large- mid- and small-cap stocks have an upside potential of up to 31% in 1 year, according to analystsAs nothing can be ruled out on the street, be prepared for anything. Now, what is the probability that the bears will be chased away from t...
- Eli Lilly brings monthly Alzheimer's therapy donanemab to India at ₹91,688 per vialEli Lilly is making Alzheimer's a major focus for its future innovations. The company is also expanding its specialty medicine offerings in...
- Alzheimer's a key part of Eli Lilly's India specialty medicine push, says company's country head Winselow TuckerEli Lilly has introduced Lormalzi in India, a pioneering treatment for Alzheimer's that specifically targets amyloid plaques, a significant...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsAs far as India is concerned, the biggest pain point from the US-Iran war in the Gulf region has been the spike in the prices of not only o...
- Pharma Q4 outlook mixed: Hospitals steady, generics face revlimid dragIndian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...
- Compliance squeeze, global scrutiny redefine India’s $30 billion pharma export playbookAs global markets prioritise quality and regulatory trust, India’s pharma sector is recalibrating beyond its traditional cost advantage.
- Walmart breaks its no-frills mold with in-store beauty experts and personalised adviceWalmart is bringing beauty experts to its stores. These trained staff will offer personalized makeup and skincare advice. This move aims to...
- Walmart’s beauty push gets personal with in-store consultationsWalmart is bringing trained beauty experts to its stores. These specialists will offer personalized makeup and skincare advice. This initia...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 25%If you are putting fresh money into the market, it might be a good idea to stay with companies that don't have much to do with global suppl...
- Drug regulator oversight sought for nutraceuticals; NGO flags quality, pricing concernsA Gujarat NGO is pushing the government to regulate nutraceuticals like medicines. They cite concerns about product quality and unregulated...
- Biocon rolls out two biosimilars in US marketBiocon has launched two new biosimilar medicines, Bosaya and Aukelso, in the United States. These drugs treat serious bone conditions. They...
- MrMed ventures into physical retail space with launch of store in ChennaiMrMed is set to inaugurate its inaugural physical store in Greams Road, Chennai on 25 April.
Load More
